ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately.
Mr. Lieber has over 30 years of financial and strategic leadership experience in the biotechnology and life sciences industries, coupled with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer of Rallybio, a clinical-stage biotechnology company developing therapies for serious and rare diseases. Having served as a senior executive and board member of various publicly traded companies, he also brings valuable Nasdaq market governance experience to IPA.
We are delighted to welcome Jon Lieber to the IPA Board of Directors during this transformative time for the Company,” said Dr. Jennifer Bath, CEO of ImmunoPrecise. “Mr. Lieber brings a rare and valuable combination of Nasdaq-listed corporate governance and corporate leadership experience, which is critical to our commercialization and growth strategies. His deep knowledge of the capital markets and proven track record of success in leading innovative companies are perfectly aligned with our strategy to expand the adoption of our LENSai™ and HYFT® platforms and position IPA at the forefront of AI-driven drug discovery.
Prior to joining Rallybio, Mr. Lieber served as Chief Financial Officer of Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company. There, he led all fundraising and oversaw finance, human resources, investor relations, and information technology. He also held senior positions at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Previously, he worked in investment banking at Salomon Brothers / Salomon Smith Barney and SG Cowen.
Mr. Lieber currently serves on the board of directors of Salarius Pharmaceuticals, where he is a member of the Audit Committee and the Nominating and Governance Committee, further highlighting his extensive experience in the governance of Nasdaq-listed companies.
“I am thrilled to join IPA’s Board of Directors at this pivotal time,” said Mr. Lieber. “The Company’s ability to integrate in silico discovery with translational biology sets it apart in the ever-changing biotherapeutics landscape. I look forward to supporting IPA’s continued momentum and strategic execution.”
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise (NASDAQ: IPA) is a global leader in the discovery and development of AI-powered biotherapeutics. Its proprietary HYFT technology and LENSai™ platform enable first-principles drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics with data-driven, human-relevant models.
This press release contains forward-looking statements within the meaning of applicable U.S. and Canadian securities laws. Forward-looking statements are often identified by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” or similar expressions, or statements that certain actions, events or results “may,” “will,” or “could” occur or be achieved. These statements include, but are not limited to, those regarding Mr. Lieber’s anticipated contributions to the Board of Directors and the strategic direction of the Company, the Company’s growth trajectory, and its ability to successfully execute scientific, business, and capital markets initiatives.
Forward-looking statements are based on management’s current expectations, assumptions and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company’s control. These factors include, but are not limited to, changes in leadership dynamics, evolving business strategies, market conditions, regulatory developments, scientific and technological advances, and other risks related to the Company’s business and industry.
